Abstract
Twenty-five patients with measurable lesions of advanced malignant melanoma received a combined chemotherapy containing cis-dichlordiammineplatinum (II) (cisplatin) 30 mg daily at days 1, 3, 5, 7, 9, and ifosfamide 45 mg/kg at days 2, 4, 6, 8, and 10. Most of the patients had been previously treated with DTIC or DTIC-containing combinations. An objective response was observed in 10 patients including three complete and seven partial remissions. Medium survival was 3 months for nonresponders and 6 months for responders. Nausea and vomiting during chemotherapy could be reduced effecttively by the use of levomepromacine (Neurocil). Hematologic toxicity was considerable in extensively pretreated patients and made it necessary to postpone subsequent courses in two cases.
Key words: Malignant melanoma, Chemotherapy, Ifosfamide, Cisplatin
Abstract
Fünfundzwanzig Patienten mit metastasierendem malignem Melanom und gut dokumentierbaren Tumorparametern wurden mit einer kombinierten zytostatischen Chemotherapie, bestehend aus Cisplatin und Ifosfamid, behandelt. Cisplatin wurde an den Tagen 1, 3, 5, 7 und 9 in der Tagesdosis von 30 mg und Ifosfamid in einer Dosis von 45 mg/kg an den Tagen 2, 4, 6, 8 und 10 verabreicht. Die meisten Patienten waren zuvor mit DTIC oder DTIC-haltigen zytostatischen Kombinationen behandelt worden. In drei Fällen wurde eine komplette Remission und in sieben Fällen eine Teilremission mit über 50% Tumorreduktion erreicht. Die mittlere Überlebenszeit betrug für therapieresistente Fälle 3 Monate und für Ansprecher 6 Monate. Erbrechen und Übelkeit während der Behandlung konnte durch die Verabreichung von Levomepromazin (Neurocil) reduziert werden. Die hämatologische Toxizität war bei intensiv vorbehandelten Patienten erheblich und machte eine Verlängerung des therapiefreien Intervalls in zwei Fällen erforderlich.
Schlüsselwörter: Malignes Melanom, Chemotherapie, Ifosfamid, Cisplatin
References
- Ahmann DL, Edmonson JH, Frytak S, Kvols LK, Bisel HF, Rubin J (1978) Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum (II) and DTIC in patients with disseminated malignant melanoma. Cancer Treatment Rep 62:151–153 [PubMed] [Google Scholar]
- Al-Sarraf M (1979) Clinical trial of cis-platinum (NSC-119875): Hydratation with and without mannitol in patients with previously treated advanced malignant melanoma. A Southwest Oncology Group Study. Proc Am Assoc Cancer Res 20:185, Abstr 746 [Google Scholar]
- Chary KK, Higby DJ, Henderson ES, Swinerton KD (1977) Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis. Cancer Treatment Rep 61:367–370 [PubMed] [Google Scholar]
- DeVita VT Jr, Fisher RI (1976) Natural history of malignant melanoma as related to therapy. Cancer Treatment Rep 60:153–157 [PubMed] [Google Scholar]
- Einhorn LH, Burgess MA, Vallejos C, Bodey GP, Gutterman J, Mavligit G, Hersh EM, Luce JK, Frei E III, Freireich EJ, Gottlieb JA (1974) Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res 34:1995–2004 [PubMed] [Google Scholar]
- Friedman MA, Kaufman DA, Williams JE, Resser KJ, Rosenbaum EH, Cohen RJ, Glassberg AB, Blume MR, Gershow J, Chan EYC (1979) Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: A Northern California Oncology Group Study. Cancer Treatment Rep 63:493–495 [PubMed] [Google Scholar]
- Getaz P, Karakousis C, Bjornsson S, Henderson E, Irequi M, Martinez L, Ospina J, Cavins J, Preisler H, Holyoke E (1979) Diamminodichloroplatinum (DDP) and dimethyl imidazole carboxamide (DTIC) in malignant melanoma. Proc Am Assoc Cancer Res K Am Soc Clin Oncol 20:351, Abstr C-246 [Google Scholar]
- Higi M, Niederle N, Bierbaum W, Schmidt CG, Seeber S (1980) Pronounced antiemetic activity of the antipsychotic drug Levomepromacine (L) in patients receiving cancer chemotherapy. J Cancer Res Clin Oncol 97:81–86 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Osieka R, Becher R, Schmidt CG (1980) Molecular pharmacology studies on human cancer xenografts. In: Bastert G, Schmidt-Mathiesen H, Fortmeyer HP (Hrsg) Thymus-aplastische Nacktmäuse und Ratten in der klinischen Onkologie. Symposium, Frankfurt a.M., 11.–15. Juni 1979. Fischer, Stuttgart New York (im Druck) [Google Scholar]
- Scheulen ME, Niederle N, Bierbaum W, Higi M, Schilcher RB, Seeber S, Schmidt CG (1980) Isophosphamide in refractory metastasized tumors: a clinical phase II study. In: Nelson JD, Grassi C (eds) Current Chemotherapy and Infectious Disease. Proceedings of the 11th Internationale Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, Massachusetts, October 1–5 1979. American Society for Microbiology, Washington, DC [Google Scholar]
- Sirica A, Venditti JM, Kline I (1971) Enhanced survival response of L 1210 leukemic mice to a single combination treatment with cis-platinum(II) diamminodichloride (CIS-PT-II; NSC-119875) plus cyclophosphamide (CY; NSC-26271). Proc Am Assoc Cancer Res 12:4 Abstr 15 [Google Scholar]
- Wagner DE, Ramirez G, Weiss AJ, Hill G Jr (1971) Combination Phase I–II study of imidazole carboxamide (NSC-45388). Oncology 26:310–316 [DOI] [PubMed] [Google Scholar]
- Woodman RJ, Sirica AE, Gang M, Kline I, Venditti JM (1973) The enhanced therapeutic effect of cisplatium(II) diamminodichloride against L 1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-l-yl) propane or several other antitumor agents. Chemotherapy 18:169–183 [DOI] [PubMed] [Google Scholar]